A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 48/00 (2006.01) A61K 39/395 (2006.01)
Patent
CA 2570017
The present invention concerns cancer therapy employing an expression construct that affects regulation of one or more particular nucleic acid sequences that encodes a gene product to which an agent is then targeted. In specific embodiments, the present invention relates to the use of p53 gene therapy to treat cancers in combination with ErbituxTM(cetuximab). Viral and non-viral gene delivery systems are disclosed.
L'invention concerne une thérapie anticancéreuse qui fait intervenir un produit de recombinaison d'expression qui affecte la régulation d'une ou de plusieurs séquences d'acides nucléiques spécifiques codant un produit génique ciblé ultérieurement par un agent. Dans des modes de réalisation spécifiques, l'invention concerne l'utilisation de la thérapie génique par p53 pour traiter le cancer, en association avec l'Erbitux<SP>TM</SP>(cetuximab). Par ailleurs, l'invention concerne des systèmes d'apport de gènes viraux et non viraux.
Chada Sunil
Roth Jack A.
Schumacher Guido
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
Board Of Regents The University Of Texas System
Introgen Therapeutics Inc.
LandOfFree
Combination treatment of cancer with elicitor of gene... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination treatment of cancer with elicitor of gene..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination treatment of cancer with elicitor of gene... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1804908